ArticleThe oncologist2017

First-Line Palliative HER2-Targeted Therapy in HER2-Positive Metastatic Breast Cancer Is Less Effective After Previous Adjuvant Trastuzumab-Based Therapy.

Hánah N Rier et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.